A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
Cell proliferation
Gene expression
Prognostic biomarker
Serous
Uterine
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
06
11
2019
revised:
03
02
2020
accepted:
08
02
2020
pubmed:
19
2
2020
medline:
31
10
2020
entrez:
19
2
2020
Statut:
ppublish
Résumé
To develop a transcriptomic signature capable of predicting overall survival (OS) for uterine serous carcinoma (USC). RNAseq data for 58 USC patients were obtained from TCGA. Expression of 73 candidate genes was measured for 67 Augusta University (AU) samples using NanoString technology. Analysis of the TCGA RNAseq data identified 73 genes that individually predict prognosis for USC patients and an elastic net model with all 73 genes (USC73) distinguishes a good OS group with low USC73 score from a poor OS group with high USC73 score (5-year OS = 83.3% and 13.3% respectively, HR = 40.1; p = 3 × 10 The USC73 transcriptomic signature and stage independently predict OS of USC patients and the best prediction is achieved using USC73 and stage. USC73 may also serve as a therapeutic biomarker to guide patient care.
Identifiants
pubmed: 32067813
pii: S0090-8258(20)30151-7
doi: 10.1016/j.ygyno.2020.02.015
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
340-347Subventions
Organisme : NICHD NIH HHS
ID : K12 HD085817
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no potential conflicts of interest.